Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-acting pasireotide GH suppression test to predict response to Pasireotide LAR in acromegaly
2025-524253-14-00Phase 2Authorised
- Sponsor
- Germans Trias i Pujol Research Institute
- Start
- Aug 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in acromegaly, sponsored by Germans Trias i Pujol Research Institute. Planned start Aug 2026; status: authorised.
02
Drugs
pasireotide LAR
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2025-524253-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524253-14-00.